HC Wainwright Reaffirms Buy Rating for Lyell Immunopharma (NASDAQ:LYEL)

Lyell Immunopharma (NASDAQ:LYEL)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports. They currently have a $45.00 price target on the stock. HC Wainwright’s target price indicates a potential upside of 202.22% from the stock’s previous close.

Several other research firms also recently commented on LYEL. Zacks Research raised shares of Lyell Immunopharma from a “strong sell” rating to a “hold” rating in a report on Monday, May 18th. Needham & Company LLC restated a “buy” rating and set a $44.00 target price on shares of Lyell Immunopharma in a research report on Thursday, May 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lyell Immunopharma in a report on Tuesday, April 21st. Citizens Jmp assumed coverage on Lyell Immunopharma in a research note on Monday, March 9th. They set a “market outperform” rating and a $34.00 price objective on the stock. Finally, Robert W. Baird set a $49.00 price objective on Lyell Immunopharma and gave the stock an “outperform” rating in a report on Thursday, April 30th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Lyell Immunopharma has a consensus rating of “Moderate Buy” and a consensus price target of $43.00.

Lyell Immunopharma Stock Performance

Shares of LYEL opened at $14.89 on Wednesday. Lyell Immunopharma has a fifty-two week low of $7.78 and a fifty-two week high of $45.00. The business has a 50-day moving average of $20.39 and a 200 day moving average of $23.58. The firm has a market cap of $347.44 million, a P/E ratio of -1.08 and a beta of -0.09.

Lyell Immunopharma (NASDAQ:LYEL) last issued its earnings results on Wednesday, May 6th. The company reported ($1.10) earnings per share for the quarter, hitting analysts’ consensus estimates of ($1.10). Lyell Immunopharma had a negative net margin of 794,858.12% and a negative return on equity of 85.71%. The firm had revenue of $0.00 million during the quarter, compared to analyst estimates of $0.00 million. As a group, research analysts predict that Lyell Immunopharma will post -8.37 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. BBR Partners LLC bought a new position in shares of Lyell Immunopharma in the fourth quarter worth $210,000. ExodusPoint Capital Management LP bought a new stake in Lyell Immunopharma during the fourth quarter valued at $262,000. Marshall Wace LLP purchased a new position in Lyell Immunopharma during the second quarter worth about $94,000. Jane Street Group LLC purchased a new position in Lyell Immunopharma during the fourth quarter worth about $382,000. Finally, Barclays PLC increased its stake in Lyell Immunopharma by 1,239.5% in the 4th quarter. Barclays PLC now owns 15,967 shares of the company’s stock worth $491,000 after acquiring an additional 14,775 shares during the last quarter. 66.05% of the stock is owned by institutional investors.

Lyell Immunopharma Company Profile

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.